BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7579733)

  • 1. Normocalcemic hyperparathyroidism associated with relatively low 1:25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol.
    Lobo PI; Cortez MS; Stevenson W; Pruett TL
    Clin Transplant; 1995 Aug; 9(4):277-81. PubMed ID: 7579733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are low plasma levels of 25-(OH)vitamin D a major risk factor for hyperparathyroidism independent of calcitriol in renal transplant patients?
    Lomonte C; Antonelli M; Vernaglione L; Cazzato F; Casucci F; Chimienti D; Bruno A; Cocola S; Verrelli EA; Basile C
    J Nephrol; 2005; 18(1):96-101. PubMed ID: 15772930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential changes of biochemical bone parameters after kidney transplantation.
    Reinhardt W; Bartelworth H; Jockenhövel F; Schmidt-Gayk H; Witzke O; Wagner K; Heemann UW; Reinwein D; Philipp T; Mann K
    Nephrol Dial Transplant; 1998 Feb; 13(2):436-42. PubMed ID: 9509459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
    Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
    Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients.
    Marco MP; Martínez I; Amoedo ML; Borràs M; Saracho R; Almirall J; Fibla J; Fernández E
    Kidney Int; 1999 Oct; 56(4):1349-53. PubMed ID: 10504487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation.
    Gómez Marqués G; Obrador Mulet A; Vilar Gimeno A; Pascual Felip MJ; Alarcón Zurita A; Molina Guasch M; Uriol Rivera M; Munar Vila MA; Losada González P
    Transplant Proc; 2009; 41(6):2139-43. PubMed ID: 19715856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.
    Goodman WG; Ramirez JA; Belin TR; Chon Y; Gales B; Segre GV; Salusky IB
    Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Calcitriol dose optimization in the treatment of secondary hyperparathyroidism during dialysis. Results at 6 months].
    Rodríguez García M; Fernández Martín JL; Ruiz de Castañeda J; Hervás Sánchez J; Cannata Andía JB;
    Nefrologia; 2002; 22(4):370-6. PubMed ID: 12369129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G; Schmitt CP; Bianchi ML; Daccò V; Claris-Appiani A; Mehls O
    Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunoassay of carboxyl and amino terminal fragments of parathyroid hormone for the evaluation of secondary hyperparathyroidism in chronic renal failure.
    Zanella MT; Silva MC; Peres RB; Ferreira SR; Draibe SA; Vieira JG
    Braz J Med Biol Res; 1990; 23(3-4):235-43. PubMed ID: 2094538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
    Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
    Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?
    Bhan I; Shah A; Holmes J; Isakova T; Gutierrez O; Burnett SM; Jüppner H; Wolf M
    Kidney Int; 2006 Oct; 70(8):1486-94. PubMed ID: 16941023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.